Saroja Pharma Industries India Ltd
Incorporated in 2023, Saroja Pharma Ltd is mainly in the business of trading Thionyl Chloride chemical and pharmaceutical intermeddles, etc.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Capital Work-in-Progress Rs. Lakhs ・Standalone data |
|
|||
| Domestic Revenue Share (India) % ・Standalone data |
||||
| Export Revenue Share (Asia Pacific + Europe + RoW) % ・Standalone data |
||||
| IPO Funds Utilized for Manufacturing Unit Rs. Lakhs ・Standalone data |
||||
| Number of Permanent Employees count ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Resignation
- Pravin Chandak & Associates resigned as statutory auditors effective 26 October 2026; replacement will be appointed later.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Filed Regulation 74(5) certificate for quarter ended 30 September 2026.
-
Resignation of Director/KMP/SMP
- Saroja Pharma Industries India Limited has informed about Resignation of Director/KMP/SMP
-
Resignation of Director/KMP/SMP
- Saroja Pharma Industries India Limited has informed about Resignation of Director/KMP/SMP
-
Resignation
- Saroja Pharma Industries India Limited has informed regarding Resignation of Mr. Ravindra Shivaji Salaskar as Whole-time Director of the company w.e.f. October 05, 2026.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2024
from nse
Business Overview:[1]
SPIIL is in the business of trading in Pharma API, Pharma Intermediates, Chemicals, Solvents, and other pharmaceutical products, used
for human and veterinary medicine